A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency

Ji-Yeon Han, Kyu-Sung Lee, Won Hee Park, Choal Hee Park, Jeong Gu Lee, Jeong Zoo Lee, Duk Yoon Kim, Yong Gil Na, Dong Deuk Kwon, Myung-Soo Choo, Ji-Yeon Han, Kyu-Sung Lee, Won Hee Park, Choal Hee Park, Jeong Gu Lee, Jeong Zoo Lee, Duk Yoon Kim, Yong Gil Na, Dong Deuk Kwon, Myung-Soo Choo

Abstract

Objectives: Patients with overactive bladder (OAB) often have trouble perceiving urgency because of difficulties in distinguishing between urgency and desire to void. Empirical antimuscarinic treatment of patients with frequency only may be reasonable if conservative management has failed. We compared the efficacy of solifenacin in patients with frequency with or without urgency.

Materials and methods: This multicenter, 12-week, open-label, comparative, non-inferiority clinical trial assessed whether the solifenacin efficacy for frequency without urgency is non-inferior to its efficacy for frequency with urgency. All patients had micturition frequency ≥ 8 voids/day with or without urgency. Primary efficacy variable: daily frequency change at 12 weeks relative to baseline. Secondary efficacy variables: change at 12 weeks relative to baseline in Patients' Perception of Bladder Condition (PPBC), OAB Symptom Score (OABSS), and Benefit, Satisfaction, Willingness to continue (BSW) questionnaire.

Results: Of the 286 enrolled patients, 240 (83.9%) completed the study (without urgency n = 115; with urgency n = 125). Full dataset analysis revealed that the groups without and with urgency exhibited significant reductions in daily micturition frequency of -2.49 ± 0.35 (mean ± standard error) and -2.63 ± 0.37, respectively. The lower limit of the 95% two-sided CI of the comparison of the two group means was -1.14, which is smaller than the -0.8 margin of clinical equivalence. The two groups did not differ in improvement in PPBC, OABSS, or BSW scores. Both tolerated the treatment well.

Conclusions: It was not possible to verify that the solifenacin efficacy for frequency alone was non-inferior to its efficacy for OAB. Nevertheless, solifenacin tended to be effective for frequency regardless of urgency.

Trial registration: ClinicalTrials.gov NCT00979472.

Conflict of interest statement

Competing Interests: This study was funded by Astellas, Korea. However, this does not alter the authors' adherence to PLOS ONE polices on sharing data and materials.

Figures

Figure 1. Participant flowchart.
Figure 1. Participant flowchart.

References

    1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21: 167–178.
    1. Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, et al. (2005) The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 95: 335–340.
    1. Brubaker L (2004) Urgency: the cornerstone symptom of overactive bladder. Urology 64: 12–16.
    1. Abrams P, Chapple CR, Junemann KP, Sharpe S (2012) Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome. World J Urol 30: 385–392.
    1. Elinoff V, Bavendam T, Glasser DB, Carlsson M, Eyland N, et al. (2006) Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 60: 745–751.
    1. Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR (2011) Validation of the urinary sensation scale (USS). Neurourol Urodyn 30: 360–365.
    1. Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49: 1079–1086.
    1. Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, et al. (2006) Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology 68: 318–323.
    1. Lee KS, Lee HW, Choo MS, Paick JS, Lee JG, et al. (2010) Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'. BJU Int 105: 1565–1570.
    1. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, et al. (2008) The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol 54: 543–562.
    1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P (2011) Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 108: 1132–1138.
    1. Digesu GA, Khullar V, Panayi D, Calandrini M, Gannon M, et al. (2008) Should we explain lower urinary tract symptoms to patients? Neurourol and Urodyn 27: 368–371.
    1. Coyne KS, Harding G, Jumadilova Z, Weiss JP (2012) Defining urinary urgency: Patient descriptions of “gotta go”. Neurourol and Urodyn 31: 455–459.
    1. Nixon A, Colman S, Sabounjian L, Sandage B, Schwiderski UE, et al. (2005) A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 174: 604–607.
    1. Starkman JS, Dmochowski RR (2008) Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 27: 13–21.
    1. Darling R, Neilson D (2005) Convenience voids: an important new factor in urinary frequency volume chart analysis. J Urol 173: 487–489.
    1. Honjo H, Kawauchi A, Nakao M, Ukimura O, Kitakoji H, et al. (2010) Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: A community-based study. Neurourol and Urodyn 29: 1286–1289.
    1. Harvey J, Finney S, Stewart L, Gillespie J (2012) The relationship between cognition and sensation in determining when and where to void: the concept of cognitive voiding. BJU Int 110: 1756–1761.
    1. Finney SM, Andersson KE, Gillespie JI, Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98: 503–507.
    1. Panayi DC, Tekkis P, Fernando R, Khullar V (2010) Is the beneficial effect of antimuscarinics related to motor or sensory changes in the bladder? Int Urogynecol J 21: 841–845.
    1. Yamaguchi O (2010) Antimuscarinics and overactive bladder: other mechanism of action. Neurourol Urodyn 29: 112–115.
    1. Stav K, Dwyer PL, Rosamilia A (2009) Women Overestimate Daytime Urinary Frequency: The Importance of the Bladder Diary. J Urol 181: 2176–2180.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel